Logo Cellply

Cellply passed the phase 2 of Call4Innovit program and will go to San Francisco

News

Cellply passed the phase 2 of Call4Innovit program and will go to San Francisco

Cellply has passed the project selection stages of the Call4Innovit project in the Life Science and Digital Health category.

An important milestone as INNOVIT is a project promoted by the General Directorate for the Country System of the Ministry of Foreign Affairs and International Cooperation, in collaboration with the Italian Embassy in Washington and the Consulate General in San Francisco, and managed with the support of ICE – Agency for the Promotion Abroad and Internationalization of Italian Companies and the Italian Cultural Institute of San Francisco.

Emiliano Spagnolo, CEO of Cellply, and Massimo Bocchi, CSO, will participate in the acceleration batch in Silicon Valley, a program that includes mentoring sessions, networking with startups, big tech, venture capital and experts, in order to foster the internationalization of the company and the development of U.S. markets.

continue reading

You may also like

Webinar

Webinar: A new automated potency analysis technique for suspension cells

25 November 2024
Events

Cellply Named in Cohort 2 of EIC Scaling Club for EU Deep Tech Scale-ups

6 November 2024
Events

Cellply Introduces Revolutionary High-Throughput Potency Analysis Technique at SITC 39th Annual Meeting

31 October 2024
Webinar

Webinar: Uncovering hidden immune cell killing to understand anti-tumor activity

2 October 2024
Webinar

Cellply is pleased to announce its participation in European Biotech Week 2024 hosting an open webinar exploring the unique assay flexibility of VivaCyte

9 September 2024
News

Eurofins Biopharma Product Testing (BPT) Italy and Cellply announce strategic partnership to foster cell and gene therapy development through single-cell characterisation

29 August 2024
Webinar

Webinar: Rapid single cell functional characterization for cell therapy potency

12 July 2024
Events

Advancing TCR-based Cell Therapies & Bispecific Approaches

24 April 2024
Press release

Nature Biotechnology publishes research from DKFZ and Cellply highlighting novel approach for accelerating cellular immunotherapy development

19 March 2024
Events

Dual attendance for Cellply at March’s leading events in the cell therapy industry.

18 March 2024
Events

Launch of VivaCyte® at Advanced Therapies Week 2024

26 January 2024
News

Cellply launches its end-to-end single cell potency characterization platform VivaCyte

17 January 2024
Events

Cellply at Advanced Therapies Week 2024

4 January 2024
News

Cellply – Fesr programme 2021-2027

28 December 2023
Press release

Cellply concludes a new internal round of €3.6 million and extends the round to new investors!

27 September 2023
News

CellPly announces acceptance of one abstract at the CICON23 conference

18 September 2023
Press release

CellPly announces Emiliano Spagnolo as the new CEO

27 July 2023
News

L’innovazione Cellply in un articolo sulla rivista Le Scienze

4 March 2020
Events

Cellply to present new method for evaluating immunotherapy efficacy at the 61th ASH Annual Meeting

25 November 2019
News

Cellply wins the €300k Gaetano Marzotto prize and Unicredit StartLab prize

22 November 2018
Events

Cellply invited to present at the World Health Summit 2019

22 October 2018
News

Cellply selected as finalist at Lyfebulb Oncology Award

1 March 2018
Events

Cellply abstract accepted at the AACR 2018 Annual Meeting

4 February 2018
Press release

Cellply and Sant’Orsola-Malpighi Polyclinic to present one abstract on AML patient stratification with the Open Microwell platform at the 58th ASH Annual Meeting

4 November 2016
News

Cellply wins an H2020 SME Instrument Phase 1 grant

20 October 2016
Keep in touch

Need some infos?

Drop us a line or give us a ring. We love to hear from you and are happy to answer any questions.